Wendy's has launched a limited-time offer for a Dave's Single combo meal priced at $7.99. The combo includes a Dave's Single hamburger made with fresh, never frozen beef, small Hot & Crispy Fries, and a small soft drink. This promotion highlights Wendy's commitment to quality food at an affordable price, appealing to customers seeking value without compromising taste. Available at participating U.S. locations starting October 19, the deal can be ordered in-restaurant, via drive-thru, or through Wendy's app and website.
Wendy's new $7.99 Dave's Single combo meal launch comes as a backdrop to Consumer Cyclical sector activity on Pluang. For readers following this sector, here is Pluang's market snapshot as of Oct 19, 2026 19:41 WIB: out of 134 priced US Consumer Cyclical stocks, 63 rose and 51 fell today. Notable movers include ATER at USD 0.57 with a 1-day change of +1.60%, GLBE at USD 39.41 up +1.52%, and BBWI at USD 20.44 rising +1.49%, with typical hold times ranging from 20 to 63 days on Pluang.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
